Turan, G., et al. Preclinical Evaluation of the SMNP-Adjuvanted R21 Malaria Vaccine Across Multiple Mouse Strains. Vaccines (Basel), 2026 Sep 28, 14(10):861. PMID: 42931390

 In Saponin-Related Publications, Scientific Papers

This paper presents the first preclinical evaluation of the SMNP (Saponin/MPLA Nanoparticle) adjuvant specifically formulated with the R21 malaria vaccine across multiple mouse strains. Saponin-based adjuvants are of significant interest due to their ability to enhance both antibody and cellular immunity, and SMNP is a next-generation ISCOM-like platform that combines saponins with monophosphoryl lipid A (MPLA), integrating particulate saponin-mediated antigen delivery with TLR4 signaling for potent immunostimulation.

The background highlights that while existing saponin-based adjuvants like AS01 and Matrix-M have shown value in malaria vaccination, developing improved formulations can further enhance efficacy and optimize antigen dose.

This study’s importance lies in demonstrating that SMNP can effectively adjuvant the R21 malaria vaccine, inducing robust NANP-specific IgG responses across different mouse strains (BALB/c, C57BL/6, and CD1). This immunogenicity was observed even with a low antigen dose (0.1 μg), indicating a potential for dose-sparing without significantly compromising immune responses. While both low and standard doses of the R21 vaccine with SMNP delayed the onset of parasitemia in all tested mouse strains, the level of protection varied significantly based on the host’s genetic background, with BALB/c mice showing the most favorable protective profile and C57BL/6 mice demonstrating lower protection despite inducing antibody responses.

The study also highlights a strong positive correlation between higher NANP-specific IgG titers and delayed parasitemia, reinforcing the importance of anti-repeat antibodies for protection. However, antibody concentration alone was not sufficient to explain all variations in protection.

This finding suggests significant dose-sparing potential without compromising immune responses, which is crucial for improving the accessibility and scalability of next-generation malaria vaccines.

Click here to access the full scientific paper.

[arrow_forms id=’3298′]
Recent Posts

Start typing and press Enter to search